ClinicalTrials.gg
RecruitingNCT07510698AMADeuSUpdated Apr 3, 2026

Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer

An interventional study of AMADeuS Perioperative Pathway and Usual Perioperative Care in Breast Cancer, Mastectomy and Prepectoral Breast Reconstruction, sponsored by University of Rome Tor Vergata. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by University of Rome Tor Vergata · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Planned enrollment
471st of 687
100 · median 208
Started
2026
with 24 others
No phase
161 of 887
53 open now
Primary completion
2028-03
later than 255 of 349 live
Registered
861st of 887
by date

Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 471st largest by planned enrollment of the 687 interventional ones that give a count, is one of 25 that started in 2026, is one of 161 with no phase, reaches primary completion later than 255 of the 349 other live ones, and was the 861st registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

225 more — sign in →

All 231 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 887 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the AMADeuS care pathway is as safe as usual hospital care and works as well for pain control in women having mastectomy with immediate prepectoral breast reconstruction. The study will also look at quality of life, satisfaction with care, hospital resource use, and environmental impact.

The main questions it aims to answer are:

  1. Does the AMADeuS pathway control pain during the first 48 hours after surgery as well as usual hospital care?
  2. Is the AMADeuS pathway as safe as usual hospital care during the first 30 days after surgery?
  3. Can the AMADeuS pathway improve recovery, reduce hospital stay and hospital visits, and lower the environmental impact of care?

Researchers will compare the AMADeuS pathway with usual hospital care. In the AMADeuS pathway, participants will have awake surgery with monitored anesthesia care, same-day discharge when safe, and follow-up that includes telemedicine. In the usual care group, participants will receive the hospital's standard perioperative care, which usually includes admission to the ward and follow-up visits at the hospital.

Participants may be women 18 to 75 years old who need nipple-sparing or skin-sparing mastectomy with immediate prepectoral reconstruction for early breast cancer or to lower future breast cancer risk. Participants must be suitable for day surgery and telemedicine follow-up. This includes having home support during the first 24 hours after surgery and living close enough to the hospital for safe discharge.

Participants will:

  • be assigned by chance to the AMADeuS pathway or to usual hospital care have mastectomy with immediate prepectoral reconstruction report their pain during the first 48 hours after surgery
  • be checked for medical problems during the first 30 days after surgery complete questionnaires about quality of life, symptoms, and satisfaction with care during follow-up
  • have follow-up visits either through telemedicine and planned local care support or through standard hospital follow-up, depending on the group they are assigned to
Read the detailed description

Breast cancer remains one of the most common indications for mastectomy, despite the increasing use of breast-conserving approaches in selected patients. In current practice, nipple-sparing mastectomy and skin-sparing mastectomy followed by immediate implant-based reconstruction aim to maintain oncologic safety while improving aesthetic, functional, and psychosocial outcomes. Within implant-based reconstruction, the prepectoral approach avoids elevation of the pectoralis major muscle and may reduce muscle-related morbidity, postoperative pain, and animation deformity in appropriately selected participants.

Perioperative breast surgery pathways are also evolving toward higher-value care models based on enhanced recovery after surgery, opioid-sparing anesthesia, day surgery, and structured remote follow-up. Existing evidence supporting same-day discharge after mastectomy with immediate reconstruction suggests that this approach can be feasible and safe in selected patients when perioperative criteria and post-discharge support are standardized. In parallel, healthcare systems are increasingly required to consider resource use and environmental impact in addition to conventional clinical outcomes.

The AMADeuS protocol (Awake MAstectomy in Day surgery with immediate prepectoral implant reconstruction and muscle Sparing) was developed to integrate these elements into a single perioperative pathway for patients undergoing nipple-sparing or skin-sparing mastectomy with immediate prepectoral prosthetic reconstruction. The study is a prospective randomized single-center trial comparing the AMADeuS pathway with the institution's standard perioperative management. Its overall aim is to determine whether this integrated pathway can maintain clinical safety and adequate postoperative pain control while improving recovery, reducing hospital resource use, and lowering the environmental burden of care.

In the experimental arm, the AMADeuS pathway combines outpatient-oriented pre-admission planning, enhanced recovery principles, awake monitored anesthesia care with local anesthesia and interfascial locoregional blocks when appropriate, multimodal opioid-sparing analgesia, same-day discharge when discharge criteria are met, and structured telemedicine-supported follow-up. Preoperative management includes reduced fasting, carbohydrate loading, and risk-adapted thromboprophylaxis. Intraoperative management includes systematic antiemetic prophylaxis, targeted oxygen delivery, and minimization of unnecessary drug and material use according to a "do not open unless needed" approach. The operating room workflow is also organized to reduce waste through modular instrument sets opened only if required, reduced use of disposable devices, monitoring of personnel present in the room, and segregation of waste into predefined categories for environmental assessment. Postoperatively, the pathway promotes early oral intake, early mobilization, short ambulatory observation, same-day discharge when clinically appropriate, telemedicine review at 7 days, and suture removal either in clinic or through local primary care support.

In the control arm, participants undergo the same underlying surgical indication and reconstructive strategy within the hospital's usual care pathway. Standard care includes inpatient admission, perioperative management according to routine anesthetic and surgical practice, postoperative ward stay, and in-person postoperative follow-up. In this arm, anesthesia technique, airway management, instrument preparation, and operating room waste handling are left to standard institutional practice and clinician preference rather than protocolized sustainability measures.

The study is centered on early postoperative pain control as the primary efficacy objective and 30-day postoperative safety as a key safety objective. In addition, the protocol prospectively evaluates postoperative recovery, patient-reported outcomes, healthcare use, and environment-related outcome measures. Patient-reported assessments include global and breast-specific quality of life, reconstruction-related satisfaction and well-being, general health status, satisfaction with care, telemedicine satisfaction, and chronic postsurgical pain over follow-up. Environment-related measures quantify the carbon footprint of the care pathway through transport-related burden, operating room waste and resource use, and hospitalization-related impact.

The statistical framework includes randomized group comparison with intention-to-treat as the primary analytic approach, supported by per-protocol and safety analyses. The trial is powered on a non-inferiority hypothesis for early postoperative pain control. Based on the protocol assumptions, the planned enrollment is 100 participants overall, with 50 participants per group. Because uncommon postoperative adverse events would require a much larger sample size for a formal non-inferiority demonstration, the 30-day safety endpoint will be interpreted primarily through effect estimates and confidence intervals, with an additional supportive non-inferiority analysis specified in the protocol.

Overall, AMADeuS is intended to test a structured model of breast surgery that combines oncologically standard mastectomy and immediate prepectoral reconstruction with awake perioperative management, day-surgery organization, telemedicine-enabled follow-up, and sustainability-oriented operating room practices. The study is designed to evaluate whether this pathway can support a broader transition toward more efficient, patient-centered, and environmentally responsible surgical care without compromising early clinical outcomes.

03

Conditions studied

  • Breast Cancer
  • Mastectomy
  • Prepectoral Breast Reconstruction
  • ERAS Programmes

Keywords

  • Amadeus
  • Breast cancer
  • Bugs
  • mastectomy
  • nipple sparing mastectomy
  • skin sparing mastectomy
  • immediate breast reconstruction
  • prepectoral breast reconstruction
  • Carbon footprint
  • ERAS
  • Sustainable surgery
  • Patient-reported outcomes
  • Postoperative pain
  • Telemedicine
  • Same-day discharge
  • Day surgery
  • Awake breast surgery
  • Monitored anesthesia care
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  • Biologically female participants aged 18 to 75 years
  • Oncologic or prophylactic indication for nipple-sparing mastectomy or skin-sparing mastectomy with immediate prepectoral reconstruction using a definitive implant or tissue expander, including early breast cancer or a high-risk genetic condition such as BRCA
  • Eligible for prepectoral reconstruction based on clinico-anatomic criteria, including adequate skin flap thickness, no relevant vascular compromise, less than 35, and no severe prior chest radiotherapy
  • (ASA) class I to III
  • Eligible for day surgery, defined by home autonomy, caregiver availability during the first 24 hours after surgery, and distance from the hospital compatible with home management
  • Able and willing to complete telemedicine follow-up, including completion of protocol-required patient-reported outcome measures
  • Written provided

**Exclusion Criteria:**

  • Chronic opioid use or treatment for pre-existing chronic pain that could interfere with assessment of the primary postoperative pain endpoint
  • to locoregional anesthesia techniques or to the awake/monitored anesthesia care protocol, including allergy to local anesthetics, coagulation disorders, or inability to cooperate during surgery
  • Body mass index 35 or greater, or anatomic conditions contraindicating prepectoral reconstruction
  • Previous high-dose chest radiotherapy with significant tissue compromise
  • Pregnancy or breastfeeding
  • Inability to guarantee planned follow-up or lack of adequate home support
  • Psychiatric or cognitive conditions preventing correct completion of patient-reported outcome measures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    AMADeuS Pathway

    Participants assigned to this arm undergo nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction within the AMADeuS perioperative pathway. This pathway includes awake monitored anesthesia care with local anesthesia and interfascial locoregional blocks when appropriate, multimodal opioid-sparing analgesia, enhanced recovery measures, same-day discharge when discharge criteria are met, telemedicine-supported follow-up, and sustainability-oriented operating room practices.

    Other: AMADeuS Perioperative Pathway

  • Active comparator
    Usual Care Pathway

    Participants assigned to this arm undergo nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction within the institution's standard perioperative care pathway. Usual care includes inpatient admission, perioperative anesthetic and surgical management according to routine clinical practice, postoperative ward stay, discharge in the following days as clinically indicated, and standard in-person hospital follow-up.

    Other: Usual Perioperative Care

Interventions

  • OtherAMADeuS Perioperative Pathway

    Integrated perioperative care pathway for participants undergoing nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction. The pathway includes same-day admission, awake monitored anesthesia care without routine airway devices, local anesthesia and interfascial blocks when appropriate, multimodal opioid-sparing analgesia, enhanced recovery measures, same-day discharge when discharge criteria are met, telemedicine follow-up at 7 days, and sustainability-oriented operating room practices including selective opening of instrument sets and waste segregation.

  • OtherUsual Perioperative Care

    Standard institutional perioperative care for participants undergoing nipple-sparing or skin-sparing mastectomy with immediate prepectoral implant-based reconstruction. This pathway includes hospital admission according to routine practice, anesthetic management based on clinician judgment, possible use of general anesthesia or airway devices when indicated, standard inpatient postoperative stay, discharge in the following days based on clinical status, routine in-person postoperative follow-up, and standard operating room organization without protocolized sustainability measures.

06

What researchers measure

Primary outcomes

  1. Postoperative pain at rest over 48 hours

    Pain control will be assessed as the area under the curve (AUC) for Numeric Pain Rating Scale (NPRS, 0-10) pain at rest measured at 0, 2, 24, and 48 hours after surgery. Lower values indicate less postoperative pain. The primary analysis is based on non-inferiority of the AMADeuS pathway versus usual care.

    Time frame: 0 to 48 hours after surgery

  2. Major Postoperative Safety Composite at 30 days

    Composite rate of major postoperative safety events within 30 days, including Clavien-Dindo grade III or higher complications, unplanned reoperation, unplanned hospital readmission, or procedure-related emergency department access.

    Time frame: Within 30 days after surgery

Secondary outcomes

  1. Postoperative pain during movement over 48 hours

    Pain during movement will be assessed as the area under the curve (AUC) for Numeric Pain Rating Scale (NPRS, 0-10) pain during mobilization measured at 0, 2, 24, and 48 hours after surgery. Lower values indicate less postoperative pain during movement.

    Time frame: 0 to 48 hours after surgery

  2. Maximum postoperative pain over 48 hours

    Highest Numeric Pain Rating Scale (NPRS, 0-10) score recorded during the first 48 hours after surgery. Lower values indicate less severe pain.

    Time frame: 0 to 48 hours after surgery

  3. Rescue analgesic use over 48 hours

    Number of rescue analgesic administrations required during the first 48 hours after surgery.

    Time frame: 0 to 48 hours after surgery

  4. Postoperative nausea and vomiting over 48 hours

    Occurrence of postoperative nausea and vomiting recorded during the first 48 hours after surgery.

    Time frame: 0 to 48 hours after surgery

  5. Time to mobilization

    Time from the end of surgery to first mobilization, measured in hours.

    Time frame: Within 48 hours after surgery

  6. Same-day discharge rate

    Proportion of participants discharged on the day of surgery.

    Time frame: Day of surgery

  7. Length of hospital stay

    Total postoperative hospital stay, measured in days.

    Time frame: Within 30 days after surgery

  8. Chronic postsurgical pain at 3 months

    Presence of chronic postsurgical pain at 3 months, defined by persistent pain with Numeric Pain Rating Scale (NPRS) score 3 or higher, with evaluation of weekly pain frequency and functional interference.

    Time frame: 3 months after surgery

  9. Chronic postsurgical pain at 6 months

    Presence of chronic postsurgical pain at 6 months, defined by persistent pain with Numeric Pain Rating Scale (NPRS) score 3 or higher, with evaluation of weekly pain frequency and functional interference

    Time frame: 6 months after surgery

  10. Global health-related quality of life

    Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scores over follow-up.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  11. Breast cancer-specific quality of life

    Change in European Organisation for Research and Treatment of Cancer breast cancer module scores (EORTC QLQ-BR42) over follow-up.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  12. Care pathway utilization

    Organizational outcomes including number of outpatient visits, number of telemedicine visits, total duration of the care pathway in days, and involvement of primary care support.

    Time frame: From surgery through 12 months after surgery

  13. Reconstruction-related satisfaction and well-being

    Change in BREAST-Q Reconstruction scores over follow-up.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  14. General health status

    Change in Short Form-36 Health Survey (SF-36) scores over follow-up.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  15. Operating room resource use

    Operating room resource use, including operating room time, number of personnel present, number and type of surgical kits opened, and use of disposable devices.

    Time frame: During surgery

  16. Satisfaction with care

    Change in Patient Satisfaction Questionnaire Short Form (PSQ-18) scores over follow-up.

    Time frame: Baseline, 1 month, 3 months, 6 months, and 12 months

  17. Telemedicine satisfaction

    Telemedicine Satisfaction Questionnaire (TSQ) scores among participants managed in the AMADeuS pathway.

    Time frame: 1 month, 3 months, 6 months, and 12 months

  18. Carbon footprint from waste generation

    Estimated carbon dioxide equivalent emissions associated with operating room and care pathway waste, based on measured waste categories.

    Time frame: From Admission to surgical room, until hospital discharge

  19. Carbon footprint from transport

    Estimated carbon dioxide equivalent emissions related to participant travel, based on distance traveled and hospital accesses avoided.

    Time frame: From surgery through 30 days after surgery

  20. Carbon footprint from hospitalization

    Estimated carbon dioxide equivalent emissions related to hospital stay, based on length of stay and bed-day emission factors.

    Time frame: Within 30 days after surgery

07

Study locations

1 of 1 sites recruiting
  • PTV Policlinico Tor Vergata University Hospital
    Rome, Rome 00133, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual participant data underlying the results reported in publications may be shared with qualified researchers on reasonable request after publication of the primary results. Data sharing will be subject to institutional approval, compliance with applicable privacy and data protection regulations, and execution of an appropriate data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 23 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Apr 3, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07510698
Lead sponsor
University of Rome Tor Vergata
Responsible party
Gianluca Vanni (Associate Professor, University of Rome Tor Vergata) — Principal investigator
First posted
Apr 3, 2026
Start date
Apr 1, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Apr 3, 2026

Study contacts

Gianluca vanni, Associate Professor
Contact
vanni_gianluca@yahoo.it
+393395685883
Marco Materazzo, MD PhD
Contact
marco.materazzo@ptvonline.it
+393395685883
Gianluca Vanni, Associate Professor
principal investigator · University of Rome Tor Vergata

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion